16 November 2021 in Journal of the American Heart Association
Background: Intermittent fasting (IF) confers pleiotropic cardiovascular benefits including restructuring of the gut microbiome and augmentation of cellular metabolism. Pulmonary arterial hypertension (PAH) is a rare and lethal disease characterized by right ventricular (RV) mitochondrial dysfunction and resultant lipotoxicity and microbiome dysbiosis. However, the effects of IF on RV function in PAH are unexplored. Therefore, we investigated how IF altered gut microbiota composition, RV function, and survival in the monocrotaline model of PAH. Methods and Results: Male Sprague Dawley rats were randomly allocated into 3 groups: control, monocrotaline‐ad libitum feeding, and monocrotaline‐IF (every other day feeding). Echocardiography and invasive hemodynamics showed IF improved RV systolic and diastolic function despite no significant change in PAH severity. IF prevented premature mortality (30% mortality rate in monocrotaline‐ad libitum versus 0% in monocrotaline‐IF rats, P =0.04). IF decreased RV cardiomyocyte hypertrophy and reduced RV fibrosis. IF prevented RV lipid accrual on Oil Red O staining and ceramide accumulation as determined by metabolomics. IF mitigated the reduction in jejunum villi length and goblet cell abundance when compared with monocrotaline‐ad libitum. The 16S ribosomal RNA gene sequencing demonstrated IF changed the gut microbiome. In particular, there was increased abundance of Lactobacillus in monocrotaline‐IF rats. Metabolomics profiling revealed IF decreased RV levels of microbiome metabolites including bile acids, aromatic amino acid metabolites, and gamma‐glutamylated amino acids. Conclusions: IF directly enhanced RV function and restructured the gut microbiome. These results suggest IF may be a non‐pharmacological approach to combat RV dysfunction, a currently untreatable and lethal consequence of PAH.
23 February 2021 in Journal of Cardiovascular Translational Research
Venous-arterial extracorporeal membrane oxygenation (VA-ECMO) treatment for acute cardiogenic shock in patients who also have acute lung injury predisposes development of a serious complication called “north-south syndrome” (NSS) which causes cerebral hypoxia. NSS is poorly characterized and hemodynamic studies have focused on cerebral perfusion ignoring the heart. We hypothesized in NSS the heart would be more likely to receive hypoxemic blood than the brain due to the proximity of the coronary arteries to the aortic annulus. To test this, we conducted a computational fluid dynamics simulation of blood flow in a human supported by VA-ECMO. Simulations quantified the fraction of blood at each aortic branching vessel originating from residual native cardiac output versus VA-ECMO. As residual cardiac function was increased, simulations demonstrated myocardial hypoxia would develop prior to cerebral hypoxia. These results illustrate the conditions where NSS will develop and the relative cardiac function that will lead to organ-specific hypoxia. Graphical Abstract
10 January 2024 in Catheterization and Cardiovascular Interventions
Background: There is considerable debate about the hemodynamic effects of veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO).Aims: To evaluate the changes in left ventricular (LV) function, volumes, and work in patients treated with VA‐ECMO using invasive LV catheterization and three‐dimensional echocardiographic volumes.Methods: Patients on VA‐ECMO underwent invasive hemodynamic evaluation due to concerns regarding candidacy for decannulation. Hemodynamic parameters were reported as means±standard deviations or medians (interquartile ranges) after evaluating for normality. Paired comparisons were done to evaluate hemodynamics at the baseline (highest) and lowest tolerated levels of VA‐ECMO support.Results: Twenty patients aged 52.3 ± 15.8 years were included. All patients received VA‐ECMO for refractory cardiogenic shock (5/20 SCAI stage D, 15/20 SCAI stage E). At 3.0 (2.0, 4.0) days after VA‐ECMO cannulation, the baseline LV ejection fraction was 20% (15%, 27%). The baseline and lowest VA‐ECMO flows were 4.0 ± 0.6 and 1.5 ± 0.6 L/min, respectively. Compared to the lowest flow, full VA‐ECMO support reduced LV end‐diastolic volume [109 ± 81 versus 134 ± 93 mL, p = 0.001], LV end‐diastolic pressure (14 ± 9 vs. 19 ± 9 mmHg, p < 0.001), LV stroke work (1858 ± 1413 vs. 2550 ± 1486 mL*mmHg, p = 0.002), and LV pressure‐volume area (PVA) (4507 ± 1910 vs. 5193 ± 2388, p = 0.03) respectively. Mean arterial pressure was stable at the highest and lowest flows (80 ± 16 vs. 75 ± 14, respectively; p = 0.08) but arterial elastance was higher at the highest VA‐ECMO flow (4.9 ± 2.2 vs lowest flow 2.7 ± 1.6; p < 0.001).Conclusions: High flow VA‐ECMO support significantly reduced LV end‐diastolic pressure, end‐diastolic volume, stroke work, and PVA compared to minimal support. The Ea was higher and MAP was stable or minimally elevated on high flow.
1 May 2024 in JACC: Clinical Electrophysiology
3 December 2025 in JACC: Case Reports
Cardiac resynchronization therapy for systemic right ventricular dysfunction in D-transposition of the great arteries (D-TGA) and atrial switch operations usually require repeat sternotomy for epicardial lead placement. We report findings in a 33-year-old woman who underwent D-TGA and atrial baffle surgery with dual-chamber pacemaker implantation who developed progressive systemic right ventricular failure (ejection fraction: 19%) with high ventricular pacing burden. Cardiac computed tomography identified feasible coronary sinus anatomy draining into the systemic venous atrium, enabling a transvenous approach. At 12-month follow-up, she demonstrated enhanced functional capacity, reduced N-terminal pro-B-type natriuretic peptide, and narrower QRS duration. We report the first successful transvenous coronary sinus lead placement in a patient with prior atrial baffle surgery, highlighting the importance of imaging in assisting procedural planning. Imaging in the setting of D-TGA patients with right ventricular dysfunction may identify accessible coronary sinus anatomy, eliminating the need for repeat sternotomy while providing cardiac resynchronization therapy benefits.